ProfileGDS5678 / 1443485_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 60% 60% 60% 57% 58% 60% 62% 60% 60% 58% 60% 64% 59% 61% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6407660
GSM967853U87-EV human glioblastoma xenograft - Control 23.5825960
GSM967854U87-EV human glioblastoma xenograft - Control 33.5725360
GSM967855U87-EV human glioblastoma xenograft - Control 43.4132257
GSM967856U87-EV human glioblastoma xenograft - Control 53.4716158
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6605360
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.772262
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5772660
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.568960
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4907858
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.5756260
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8006964
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5788359
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6656161